Although TRAIL may be a relatively safe and promising death ligand in clinical applications, it has been reported that susceptibility to TRAIL-induced apoptosis depends on the type of cancer, and sensitive cancer cell lines may be resistant to TRAIL. Here, TNFSF10 is linked to cancer.